# Benign Prostatic Hyperplasia Treatment Devices Market

> Global Benign Prostatic Hyperplasia Treatment Devices Market Research Report By Device Type (Surgical Devices, Minimally Invasive Devices, Pharmaceutical Devices, Combination Therapy Devices), By Procedure Type (Transurethral Resection of the Prostate, Laser Therapy, Transurethral Microwave Therapy, Prostatic Urethral Lift), By End User (Hospitals, Clinics, Ambulatory Surgical Centers), By Technology (Laser Technology, Radiofrequency Technology, Mechanical Devices) andBy Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2026 To 2035

- **Forecast Period:** 2026-2035
- **CAGR:** 6.61%
- **2025:** USD 1.90 Billion
- **2035:** USD 3.61 Billion
- **Key Players:** Boston Scientific Corporation, Teleflex Incorporated, Olympus Corporation, KARL STORZ SE & Co. KG, PROCEPT BioRobotics Corporation, Richard Wolf GmbH, Coloplast A/S, Dornier MedTech GmbH

**Report ID:** MRFR/HC/41441-HCR · **Pages:** 200 · **Author:** Rahul Gotadki & Vikita Thakur · **Last Updated:** November 03, 2026

**URL:** https://www.marketresearchfuture.com/reports/benign-prostatic-hyperplasia-treatment-devices-market-43107

---

## Market Summary

## Benign Prostatic Hyperplasia Treatment Devices Market Summary

The [Benign Prostatic Hyperplasia Treatment](https://www.marketresearchfuture.com/reports/benign-prostatic-hyperplasia-treatment-market-11838) Devices Market was valued at USD 1.90 Billion in 2025. It is projected to reach USD 2.03 Billion in 2026 and USD 3.61 Billion by 2035, a CAGR of 6.61% over 2026–2035. Demographics underpin this demand. Roughly 94 million men were living with BPH worldwide in 2019 [1], and the population aged 65 and above is on course to double to 1.6 billion by 2050. Two catalysts sharpen the near-term outlook. The American Urological Association's 2023 guideline amendment broadened support for minimally invasive procedures [4], and CMS raised ambulatory surgical center payment rates by 2.9% for 2025 [12].

Technology substitution defines the Benign Prostatic Hyperplasia Treatment Devices Market this decade. Monopolar TURP, long the reference standard, is losing procedures to bipolar resection, holmium and thulium laser enucleation, water vapor therapy, prostatic urethral implants and robotic waterjet resection. PROCEPT BioRobotics had installed more than 400 robotic systems in the United States by August 2024, when its AI-guided HYDROS platform received FDA clearance [6]. Retrievable nitinol implants approved in December 2025 move more of this care into the office [8].

North America leads with a 41.2% revenue share in 2025, supported by dense urologist coverage and established reimbursement codes. Asia-Pacific is the fastest-growing region at an 8.7% CAGR, driven by ageing populations in Japan and China and expanding insurance in India. Europe holds a 27.4% share, anchored by guideline-driven laser adoption. Over the forecast period, procedure growth will increasingly come from outpatient and office settings rather than inpatient theatres.

## Key Report Takeaways

### • By Device Type

- transurethral resection devices: TURP held a 39.3% share of the Benign Prostatic Hyperplasia Treatment Devices Market in 2025, reflecting surgeon familiarity and broad reimbursement
- [radiofrequency ablation devices](https://www.marketresearchfuture.com/reports/radiofrequency-ablation-devices-market-7634) are expected to post an 8.9% CAGR through 2035 as water vapor therapy gains label expansions
- laser-based devices accounted for 22.6% of revenue, favored for large glands and anticoagulated patients

### • By End User

- hospitals captured 55.2% of Benign Prostatic Hyperplasia Treatment Devices Market spending in 2025
- surgical centers are projected to grow at a 10.2% CAGR as payers steer procedures toward lower-cost sites

### • By Region

- North America accounted for a 41.2% share in 2025
- Asia-Pacific is forecast to expand at an 8.7% CAGR, the highest of any region
- Europe represented 27.4% of the Benign Prostatic Hyperplasia Treatment Devices Market in 2025

## Market Size and Forecast (2026–2035)

Market values combine procedure-volume modelling by device category with manufacturer revenue disclosures, hospital purchasing data and reimbursement schedules. Interviews with urologists, procurement heads and distributors validate these figures. Historical figures reflect reported company segment revenue and national procedure registries, while forecasts apply region-specific adoption curves for each device class. The table below traces the Benign Prostatic Hyperplasia Treatment Devices Market from post-pandemic recovery to the end of the forecast period.

## Market Drivers

## Driver Impact Analysis

Impact percentages below indicate the directional contribution of each driver to the Benign Prostatic Hyperplasia Treatment Devices Market forecast CAGR. They are analyst estimates from scenario modelling. Because the drivers overlap, the values are not additive and should not be summed to reproduce the headline growth rate.

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Ageing male population and rising BPH prevalence | +1.6% | Global; strongest in Japan, Europe, China | Long-term (≥4 yr) | [1] |
| Shift toward function-preserving minimally invasive therapies | +1.3% | North America, Europe | Medium-term (2–4 yr) | [4][14] |
| Site-of-care migration to ambulatory settings | +1.1% | United States | Short-term (≤2 yr) | [12] |
| Robotics and AI-guided treatment planning | +0.9% | North America, Western Europe, Japan | Medium-term (2–4 yr) | [6] |
| Guideline endorsement of laser enucleation for large prostates | +0.7% | Europe, Asia-Pacific | Long-term (≥4 yr) | [5] |
| Public insurance expansion in emerging economies | +0.6% | India, Saudi Arabia, Brazil | Long-term (≥4 yr) | [18][24] |

### Ageing Male Population and Rising BPH Prevalence

With age, prevalence rises sharply. Up to 90% of men over 80 and almost half of males between the ages of 51 and 60 exhibit BPH alterations [3]. In 2019, there were almost 94 million cases worldwide, a significant increase from 2000 [1]. In Japan, 29.1% of people are 65 years of age or older [19], and the UN predicts that number will quadruple by 2050. Because many of these men eventually cease responding to medicine, this expanding pool of symptomatic men keeps surgery volumes rising regardless of short-term pricing changes.

### Shift Toward Function-Preserving Minimally Invasive Therapies

The sexual side effects of resection are increasingly rejected by patients. Water vapor therapy's five-year data revealed a 4.4% surgical retreatment rate without any new indications of sexual dysfunction [14]. Throughout its key cohort, prostatic urethral lift maintained ejaculatory function [13]. These choices for specified gland sizes were acknowledged in the 2023 AUA guideline modification [4]. Some men switch from medicine to a procedure with each guideline endorsement.

### Site-of-Care Migration to Ambulatory Settings

CMS increased ASC payment rates by 2.9% in its CY 2025 final rule and continues to add urology procedures to the ASC covered list [12]. Outpatient centers deliver the same procedures at materially lower facility cost, and commercial payers now steer eligible cases away from inpatient units. Device makers are responding with compact consoles, single-use handpieces and protocols that need less anesthesia, allowing same-day discharge. As a result, more systems are being installed outside hospital operating rooms.

### Robotics and AI-Guided Treatment Planning

Robotic waterjet resection is no longer limited to early adopters and is now common in mainstream urology programs. The FDA cleared the HYDROS platform in August 2024. Its planning software, trained on more than 50,000 procedures, maps the patient's anatomy on ultrasound [6]. Five-year WATER trial data showed durable symptom relief versus TURP in glands of 30–80 mL [15]. High-volume centers find robotic systems an attractive capital purchase because outcomes stay consistent regardless of surgeon experience.

### Guideline Endorsement of Laser Enucleation for Large Prostates

European guidelines list holmium and thulium laser enucleation as size-independent options and a first choice for glands above 80 mL [5]. Enucleation has low retreatment rates and causes less bleeding, which matters because a growing share of patients take anticoagulants. Laser generators also generate recurring revenue from fibers and morcellators, so each new enucleation program lifts consumable sales for several years after installation.

### Public Insurance Expansion in Emerging Economies

In October 2024, India extended Ayushman Bharat PM-JAY coverage to all citizens aged 70 and above. The change added roughly 60 million seniors to a scheme that pays for urological surgery [18]. Saudi Arabia's Health Sector Transformation Program targets expanded specialty capacity under Vision 2030 [24]. Wider coverage turns unmet need into paid procedures. In the early years, however, price sensitivity favors TURP and lower-cost laser systems.

## Restraints

## Restraints Impact Analysis

Restraint impacts represent directional drag on the Benign Prostatic Hyperplasia Treatment Devices Market forecast CAGR rather than additive deductions. Several restraints interact with each other and with the drivers above, so the values indicate relative weight only.

| Restraint | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| High capital cost of robotic and laser platforms | −0.9% | Global; acute in emerging markets | Medium-term (2–4 yr) | [21][22] |
| Durability concerns and retreatment rates for some MISTs | −0.7% | North America, Europe | Medium-term (2–4 yr) | [13] |
| EU MDR certification burden | −0.5% | Europe | Short-term (≤2 yr) | [16] |
| Limited reimbursement and high out-of-pocket costs in developing regions | −0.6% | South America, Middle East and Africa, South Asia | Long-term (≥4 yr) | [18] |
| Surgeon learning curves for enucleation and new platforms | −0.4% | Global | Medium-term (2–4 yr) | [5] |

### High Capital Cost of Robotic and Laser Platforms

High-power holmium lasers and robotic waterjet consoles need service agreements in addition to six-figure capital commitments. There are fewer systems installed outside of large academic centers because hospitals with limited capital budgets sometimes put off buying or leasing equipment. Manufacturers reveal that system deployments differ annually because capital sales are still influenced by hospital budget cycles and financing rates [21], [22].

### Durability Concerns and Retreatment Rates for Some MISTs

Not all minimally invasive procedures are as durable as resection. A five-year surgical retreatment rate for prostatic urethral lift was 13.6%, the L.I.F.T. research showed [13]. This is weighed against reduced upfront morbidity by payers and surgeons. Some health systems limit the volume growth of certain device classes by restricting the use of more recent implants to specific anatomical regions.

### EU MDR Certification Burden

Regulation (EU) 2023/607 extended MDR transition deadlines to December 2027 and December 2028, but recertification remains costly and slow [16]. Rather than pay for new clinical evaluations, smaller manufacturers have withdrawn legacy products from Europe. Fewer product options and delayed launches hold European growth below that of the United States.

### Limited Reimbursement and High Out-of-Pocket Costs in Developing Regions

Out-of-pocket payments still account for close to 40% of health spending in India [18], and similar patterns apply across much of South America and Africa. Patients in these markets often stay on long-term medication or choose low-cost resection. Premium devices therefore see limited uptake despite large untreated populations.

### Surgeon Learning Curves for Enucleation and New Platforms

Laser enucleation typically requires 20–50 supervised cases before outcomes stabilize [5]. Training bottlenecks restrict how quickly hospitals can add enucleation programs, and new robotic or implant platforms each require proctoring. Limited urologist supply in rural regions compounds the constraint.

## Opportunities

## Benign Prostatic Hyperplasia Treatment Devices Market Opportunities

### Office-Based Procedures in Specialty Clinics

Retrievable nitinol implants approved in December 2025, including the ProVee and Spring systems, are designed for outpatient delivery under local anesthesia [8][9]. Urology groups that add office procedure suites can earn both the professional fee and the facility fee. Vendors offering compact, single-use delivery systems are well placed to win share of the Benign Prostatic Hyperplasia Treatment Devices Market in specialty clinics.

### Emerging-Market Capacity Build-Out

China, India and the ASEAN economies combine large untreated populations with expanding hospital capacity and insurance coverage [18]. Mid-priced laser systems, bipolar resection platforms and locally manufactured consumables fit the price limits in these markets. Distribution partnerships and surgeon training academies are the main ways to enter.

### Procedure Data and Per-Procedure Business Models

Robotic platforms collect imaging and outcome data from every case, which improves their planning algorithms [6]. Vendors can earn revenue from this through software subscriptions, outcome benchmarking services for hospitals, and per-procedure pricing that folds the capital cost into consumable fees. These models make it easier for mid-sized hospitals to buy in and give vendors recurring revenue.

### Next-Generation Prostatic Stents and Retrievable Implants

Prostatic stents historically served frail, high-risk patients. Newer designs target first-line intervention for 30–80 cc glands, the gland size of most BPH patients [9]. Several more devices are in clinical development, including the FloStent system now in the RAPID III study [11].

### Single-Use Endoscopy Integration

Single-use cystoscopes, such as the Spring scope cleared in September 2025 [10], remove reprocessing costs and infection risk. Packaging a disposable scope with the implant delivery system gives ambulatory operators a complete procedure kit.

## Future Outlook

## Benign Prostatic Hyperplasia Treatment Devices Market Future Outlook

### AI-Guided Planning and Procedural Standardization

Planning software trained on tens of thousands of cases already guides robotic resection [6]. In the next phase, imaging-based analysis will also help choose which device to use. Combined ultrasound, MRI and symptom-score analytics are likely to recommend the best treatment for each gland. Vendors with the largest outcome datasets will hold a structural advantage in this Benign Prostatic Hyperplasia Treatment Devices Market.

### Consumable-Led and Per-Procedure Economics

Revenue in the Benign Prostatic Hyperplasia Treatment Devices Market will keep moving from capital equipment to single-use handpieces, fibers, implants and delivery systems. Per-procedure pricing lowers the upfront cost for hospitals and makes manufacturer revenue more predictable. Device makers report that recurring consumables already make up a growing share of urology segment sales [21][22].

### Decentralization of Care

By 2030, 1 in 6 people worldwide is projected to be over 60. Health systems cannot handle the resulting volumes in inpatient theatres alone. By the mid-2030s, office-based implants, prostate tissue ablation under local anesthesia and single-use scopes will move a growing share of procedures into clinics and ambulatory centers.

### Evidence Generation and Sustainability

Payers increasingly demand five-year durability data before granting favorable coverage, as seen with water vapor, implant and waterjet therapies [13][14][15]. Hospitals are also examining the environmental impact of single-use devices, pushing manufacturers toward recyclable packaging and reprocessing programs.

## Segment Insights

## Benign Prostatic Hyperplasia Treatment Devices Market Segmentation

### By Device Type

| Segment | Key Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| laser-based devices | 22.6% share | Large-gland enucleation and hemostasis in anticoagulated patients |
| transurethral resection devices: TURP | 39.3% share | Established technique, broad reimbursement, surgeon familiarity |
| radiofrequency ablation devices | 8.9% CAGR (2026–2035) | Water vapor therapy label expansion and office use |
| UroLift systems | USD 0.21 Billion | Preservation of ejaculatory function |
| microwave thermotherapy devices | USD 0.07 Billion | Anesthesia-free option for high-risk patients |
| high-intensity focused ultrasound (HIFU) devices | 5.4% CAGR (2026–2035) | Non-invasive transrectal ablation research |
| others: catheters, prostatic stents, among others | 6.2% share | Retrievable implants and post-procedure catheter demand |

Within the Benign Prostatic Hyperplasia Treatment Devices Market, transurethral resection devices: TURP remain the largest revenue source because bipolar resection is reimbursed nearly everywhere and taught in every residency. Laser-based devices rank second because enucleation performs well in large glands. Radiofrequency ablation devices are growing fastest after the 2025 Rezūm label expansion to 150 cm³ [7], while UroLift systems serve sexually active men. The others category, which includes catheters and prostatic stents, is growing on the back of new retrievable implants [8].

### By End User

| Segment | Key Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| hospitals | 55.2% share | Complex comorbid cases and capital-intensive platforms |
| ambulatory | USD 0.27 Billion | Same-day outpatient pathways and lower facility costs |
| surgical centers | 10.2% CAGR (2026–2035) | Payer site-of-care steering and rising ASC payment rates |
| specialty clinics | 8.1% CAGR (2026–2035) | Office-based implants under local anesthesia |

Hospitals lead the Benign Prostatic Hyperplasia Treatment Devices Market by end user because large glands, anticoagulated patients and robotic systems require full surgical infrastructure. Surgical centers post the fastest growth as CMS payment updates and commercial payer policies redirect eligible cases [12]. Ambulatory settings take on more vapor and implant procedures, and specialty clinics are growing as retrievable implants become available in the office [9].

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Key Metric (2025) | Primary Investment Themes |
| --- | --- | --- |
| North America | 41.2% share | Robotic waterjet installations, ASC expansion, implant launches |
| Europe | 27.4% share | Laser enucleation programs, MDR recertification, backlog reduction |
| Asia-Pacific | 8.7% CAGR (2026–2035) | Hospital capacity growth, insurance expansion, ageing populations |
| South America | 5.1% share | Private hospital investment, bipolar resection adoption |
| Middle East and Africa | 4.5% share | Gulf specialty hospital build-out, medical tourism |
| Total | USD 1.90 Billion | — |

Regional performance in the Benign Prostatic Hyperplasia Treatment Devices Market depends on reimbursement maturity, urologist density and population age structure. North America and Europe together generate more than two-thirds of revenue, while Asia-Pacific adds the most new procedure volume.

### North America

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| US | 87.6% of regional revenue | ASC reimbursement, robotic and implant adoption |
| Canada | 6.9% CAGR (2026–2035) | Provincial wait-time reduction programs |
| Mexico | USD 0.03 Billion | Private hospital growth and medical tourism |

The United States drives the regional Benign Prostatic Hyperplasia Treatment Devices Market through high procedure volumes, early access to newly approved devices and favorable outpatient payment rules [12]. FDA decisions in 2024 and 2025 added new robotic, implant and vapor-therapy options [6][7][8]. Canada's public systems adopt new devices more slowly but prioritize day-surgery procedures to cut waiting lists. Mexico's private hospitals serve both domestic and cross-border patients.

### Europe

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| Germany | 24.8% of regional revenue | Hospital Future Act digital and equipment funding |
| UK | 6.4% CAGR (2026–2035) | NHS elective recovery and NICE technology guidance |
| France | USD 0.08 Billion | Laser enucleation adoption in public hospitals |
| Italy | 11.6% of regional revenue | Ageing population and regional procurement tenders |
| Spain | 6.1% CAGR (2026–2035) | Day-surgery expansion |
| Nordic Countries | USD 0.03 Billion | Outcome-registry driven technology selection |
| Russia | 4.2% of regional revenue | Domestic substitution of imported equipment |
| Rest of Europe | 5.3% CAGR (2026–2035) | EU structural funds for hospital modernization |

Germany leads the European Benign Prostatic Hyperplasia Treatment Devices Market, supported by EUR 4.3 billion in Hospital Future Act funding for modernization [17]. The UK's elective recovery plan committed about GBP 8 billion over three years to reduce backlogs [20], and NICE guidance supports water vapor therapy in eligible patients [25]. Across the region, EU MDR recertification decides which devices stay on the market [16].

### Asia-Pacific

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| China | 33.5% of regional revenue | Tertiary hospital expansion and volume-based procurement |
| India | 11.2% CAGR (2026–2035) | PM-JAY coverage for seniors aged 70+ |
| Japan | USD 0.10 Billion | Super-aged population and laser enucleation expertise |
| South Korea | 7.8% of regional revenue | National insurance coverage of laser procedures |
| ASEAN | 10.1% CAGR (2026–2035) | Private hospital chains and medical tourism |
| Rest of Asia-Pacific | USD 0.04 Billion | Australia's early adoption of minimally invasive options |

Asia-Pacific is the fastest-growing regional Benign Prostatic Hyperplasia Treatment Devices Market. In Japan, 29.1% of residents are aged 65 or older, creating a large patient pool [19]. India's insurance expansion brings surgical BPH care within reach of millions of older men [18]. China's volume-based procurement lowers consumable prices but raises procedure counts, which favors manufacturers that produce locally.

### South America

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| Brazil | 54.2% of regional revenue | Private insurer networks and urology centers of excellence |
| Argentina | 6.8% CAGR (2026–2035) | Replacement of monopolar resection equipment |
| Rest of South America | USD 0.02 Billion | Gradual private-sector investment in Chile and Colombia |

Brazil dominates regional spending through a large private insurance sector serving urban populations. In Argentina, currency volatility delays capital purchases, though bipolar resection and laser systems are gradually replacing monopolar equipment. Across the region, high out-of-pocket costs keep TURP as the default intervention for most patients.

### Middle East and Africa

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| Saudi Arabia | 28.6% of regional revenue | Vision 2030 health sector transformation |
| UAE | 9.4% CAGR (2026–2035) | Medical tourism and premium private hospitals |
| South Africa | USD 0.02 Billion | Private hospital groups and medical schemes |
| Egypt | 9.8% of regional revenue | Universal Health Insurance rollout |
| Rest of MEA | 6.2% CAGR (2026–2035) | Donor-funded surgical capacity building |

Gulf states account for most regional device value. Saudi Arabia's Health Sector Transformation Program funds specialty hospital capacity and moves more care delivery to private providers [24]. The UAE markets premium urology services to international patients. In Sub-Saharan Africa, too few urologists and reliance on basic resection equipment hold the market back.

## Competitive Benchmarking

## Competitive Benchmarking

The Benign Prostatic Hyperplasia Treatment Devices Market shows medium concentration, with an estimated Herfindahl-Hirschman Index of about 1,100–1,200. The five largest suppliers account for an estimated 55–60% of revenue. Many smaller laser, implant and regional resection manufacturers compete on price and niche indications. Companies compete mainly on clinical evidence, consumable costs and suitability for outpatient settings, not just on equipment price.

| Company | Est. Revenue Share Range | Key Offerings for benign prostatic hyperplasia treatment devices market | Strategic Positioning |
| --- | --- | --- | --- |
| Boston Scientific Corporation | ~14–18% | Rezūm water vapor system, MOSES holmium lasers, laser fibers | Broadest portfolio spanning office, ASC and hospital settings |
| Teleflex Incorporated | ~11–14% | UroLift System, UroLift 2 | Leader in implant-based, function-preserving therapy |
| Olympus Corporation | ~10–13% | Bipolar TURis resectoscopes, iTind, thulium lasers | Endoscopy installed base and resection leadership |
| KARL STORZ SE & Co. KG | ~7–10% | Resectoscopes, cystoscopes, morcellators | Visualization and instrument depth in hospitals |
| PROCEPT BioRobotics Corporation | ~6–9% | HYDROS and AquaBeam robotic systems | Robotic waterjet pioneer with AI planning |
| Richard Wolf GmbH | ~4–6% | Resectoscopes, MegaPulse lasers | European hospital and laser enucleation focus |
| Coloplast A/S | ~3–5% | Urinary catheters, prostatic stents | Post-procedure and catheter consumables |
| Dornier MedTech GmbH | ~2–4% | Medilas laser systems, urology tables | Mid-priced laser platforms for emerging markets |
| Quanta System S.p.A. | ~1–3% | Cyber Ho and thulium fiber lasers | High-power laser innovation |
| Urologix, LLC | ~1–3% | Cooled ThermoTherapy microwave systems | Office-based thermal therapy niche |
| SonaCare Medical, LLC | ~1–2% | Sonablate HIFU platform | Focused ultrasound ablation specialist |

## Recent News & Developments

## Recent News & Developments

- American Urological Association (2023): Amended its BPH surgical management guideline, refining recommendations for minimally invasive and size-specific procedures; payers use the guideline in coverage decisions [4]
- PROCEPT BioRobotics (August 2024): Received FDA 510(k) clearance for the HYDROS Robotic System with AI-powered treatment planning, with more than 400 systems already installed in the US [6]
- Rivermark Medical (April 2025): Enrolled the first patient in the RAPID III study of the FloStent System, adding to the pipeline of implant-based options [11]
- Boston Scientific (June 2025): Secured FDA 510(k) clearance expanding Rezūm treatment to prostates up to 150 cm³ from 80 cm³, widening the eligible patient pool [7]
- Zenflow (September 2025): Obtained FDA 510(k) clearance for its single-use Spring scope and camera control unit, simplifying procedures in the office [10]
- ProVerum (December 2025): Won FDA premarket approval for the ProVee System, a nitinol prostatic urethral expander for 30–80 cc glands [8]
- Zenflow (December 2025): Received FDA approval for the Spring implant system, a retrievable nitinol device for first-line intervention [9]

## Report Scope

| Parameter | Details |
| --- | --- |
| Market Scope | Devices used to treat BPH, including resection, laser, radiofrequency, implant, thermotherapy, HIFU, catheter and stent systems sold to hospitals, ambulatory facilities, surgical centers and specialty clinics |
| Study Period | 2021–2035 |
| Base Year | 2025 |
| Historical Data | 2021–2024 |
| Forecast Period | 2026–2035 |
| Market Size in 2025 | USD 1.90 Billion |
| Market Size in 2035 | USD 3.61 Billion |
| CAGR (2026–2035) | 6.61% |
| Fastest Growing Segments | surgical centers (10.2% CAGR); radiofrequency ablation devices (8.9% CAGR); specialty clinics (8.1% CAGR) |
| Regions Covered | North America, Europe, South America, Asia Pacific, Middle East and Africa and ROW |
| Companies Profiled | Boston Scientific Corporation, Teleflex Incorporated, Olympus Corporation, KARL STORZ SE & Co. KG, PROCEPT BioRobotics Corporation, Richard Wolf GmbH, Coloplast A/S, Dornier MedTech GmbH, Quanta System S.p.A., Urologix LLC, SonaCare Medical LLC |
| Valuation Currency | USD Billion |
| Methodology | 350+ primary expert interviews; bottom-up market sizing; top-down validation; data triangulation; scenario-based forecasting; real-time project tracking |

## Frequently Asked Questions

**Q: How should hospitals evaluate capital purchases in the Benign Prostatic Hyperplasia Treatment Devices Market?**
A: Buyers in the Benign Prostatic Hyperplasia Treatment Devices Market should model cost per procedure over five years, including consumables, service contracts and expected case volume. Platforms with shared consoles across urology indications usually deliver faster payback [23].

**Q: Which procurement models are gaining traction in the Benign Prostatic Hyperplasia Treatment Devices Market?**
A: Placement agreements that bundle capital into per-procedure consumable fees are spreading among mid-sized hospitals. They shift utilization risk to manufacturers and protect capital budgets.

**Q: What differentiates retrievable implants from permanent implants?**
A: Retrievable devices in the Benign Prostatic Hyperplasia Treatment Devices Market can be removed without tissue damage, preserving future surgical options. This reversibility appeals to younger men who want to avoid committing to irreversible procedures [9].

**Q: How do regulatory pathways differ for new BPH devices in the United States?**
A: Novel permanent implants often require premarket approval with pivotal trial data, while iterative platforms typically use the 510(k) route. PMA timelines and evidence costs are substantially higher [8].

**Q: What integration challenges do ambulatory operators face in the Benign Prostatic Hyperplasia Treatment Devices Market?**
A: Operators must align anesthesia protocols, ultrasound imaging and sterile processing with fast patient turnover. Single-use scopes and compact consoles reduce those workflow burdens [10].

**Q: Which emerging use cases could expand demand for BPH devices?**
A: Treatment of men with median-lobe enlargement and very large glands is widening as label expansions accumulate. Combination approaches pairing implants with medication withdrawal are also under study [7].

**Q: What competitive risk do new entrants face?**
A: Incumbents in the Benign Prostatic Hyperplasia Treatment Devices Market control surgeon training networks and hospital value-analysis committees. New entrants usually need head-to-head or long-term durability data before winning formulary placement [15].


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/benign-prostatic-hyperplasia-treatment-devices-market-43107*
